Cargando…

Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review

BACKGROUND: Renal angiomyolipoma (AML) is the most frequent mesenchymal tumor of the kidney. Although there is a rare possibility of malignant transformation of AML, this risk has not been studied in immunosuppressed patients. The safety of donors with AML and their kidney transplant recipients has...

Descripción completa

Detalles Bibliográficos
Autores principales: Anton, Desiree Garcia, Kovvuru, Karthik, Kanduri, Swetha R, Aeddula, Narothama Reddy, Bathini, Tarun, Thongprayoon, Charat, Kaewput, Wisit, Wijarnpreecha, Karn, Watthanasuntorn, Kanramon, Salim, Sohail Abdul, Matemavi, Praise, Vaitla, Pradeep, Rivera, Franco Cabeza, Cheungpasitporn, Wisit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052899/
https://www.ncbi.nlm.nih.gov/pubmed/33897168
http://dx.doi.org/10.4103/UA.UA_14_20
_version_ 1783680017515937792
author Anton, Desiree Garcia
Kovvuru, Karthik
Kanduri, Swetha R
Aeddula, Narothama Reddy
Bathini, Tarun
Thongprayoon, Charat
Kaewput, Wisit
Wijarnpreecha, Karn
Watthanasuntorn, Kanramon
Salim, Sohail Abdul
Matemavi, Praise
Vaitla, Pradeep
Rivera, Franco Cabeza
Cheungpasitporn, Wisit
author_facet Anton, Desiree Garcia
Kovvuru, Karthik
Kanduri, Swetha R
Aeddula, Narothama Reddy
Bathini, Tarun
Thongprayoon, Charat
Kaewput, Wisit
Wijarnpreecha, Karn
Watthanasuntorn, Kanramon
Salim, Sohail Abdul
Matemavi, Praise
Vaitla, Pradeep
Rivera, Franco Cabeza
Cheungpasitporn, Wisit
author_sort Anton, Desiree Garcia
collection PubMed
description BACKGROUND: Renal angiomyolipoma (AML) is the most frequent mesenchymal tumor of the kidney. Although there is a rare possibility of malignant transformation of AML, this risk has not been studied in immunosuppressed patients. The safety of donors with AML and their kidney transplant recipients has not been well established. METHODS: A literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane databases from inception through May 15, 2018 (updated on October 2019). We included studies that reported the outcomes of kidney donors with AML or recipients of donor with AML. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018095157). RESULTS: Fourteen studies with a total of 16 donors with AML were identified. None of the donors had a diagnosis of tuberous sclerosis complex (TSC), pulmonary lymphangioleiomyomatosis (LAM), or epithelioid variant of AML. Donor age ranged from 35 to 77 years, and recipient age ranged from 27 to 62 years. Ninety-two percent of the donors were female. Only 8% were deceased donor renal transplant. The majority underwent ex vivo resection (65%) before transplantation, followed by no resection (18%), and the remaining had in vivo resection. Tumor size varied from 0.4 cm to 7 cm, and the majority (87%) were localized in the right kidney. Follow-up time ranged from 1 to 107 months. Donor creatinine prenephrectomy ranged 0.89–1.1 mg/dL and postnephrectomy creatinine 1.0–1.17 mg/dL. In those who did not have resection of the AML, tumor size remained stable. None of the donors with AML had end-stage renal disease or died at last follow-up. None of the recipients had malignant transformation of AML. CONCLUSION: These findings are reassuring for the safety of donors with AML (without TSC or LAM) as well as their recipients without evidence of malignant transformation of AML. As such, this can also positively impact the donor pool by increasing the number of available kidneys.
format Online
Article
Text
id pubmed-8052899
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-80528992021-04-23 Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review Anton, Desiree Garcia Kovvuru, Karthik Kanduri, Swetha R Aeddula, Narothama Reddy Bathini, Tarun Thongprayoon, Charat Kaewput, Wisit Wijarnpreecha, Karn Watthanasuntorn, Kanramon Salim, Sohail Abdul Matemavi, Praise Vaitla, Pradeep Rivera, Franco Cabeza Cheungpasitporn, Wisit Urol Ann Original Article BACKGROUND: Renal angiomyolipoma (AML) is the most frequent mesenchymal tumor of the kidney. Although there is a rare possibility of malignant transformation of AML, this risk has not been studied in immunosuppressed patients. The safety of donors with AML and their kidney transplant recipients has not been well established. METHODS: A literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane databases from inception through May 15, 2018 (updated on October 2019). We included studies that reported the outcomes of kidney donors with AML or recipients of donor with AML. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018095157). RESULTS: Fourteen studies with a total of 16 donors with AML were identified. None of the donors had a diagnosis of tuberous sclerosis complex (TSC), pulmonary lymphangioleiomyomatosis (LAM), or epithelioid variant of AML. Donor age ranged from 35 to 77 years, and recipient age ranged from 27 to 62 years. Ninety-two percent of the donors were female. Only 8% were deceased donor renal transplant. The majority underwent ex vivo resection (65%) before transplantation, followed by no resection (18%), and the remaining had in vivo resection. Tumor size varied from 0.4 cm to 7 cm, and the majority (87%) were localized in the right kidney. Follow-up time ranged from 1 to 107 months. Donor creatinine prenephrectomy ranged 0.89–1.1 mg/dL and postnephrectomy creatinine 1.0–1.17 mg/dL. In those who did not have resection of the AML, tumor size remained stable. None of the donors with AML had end-stage renal disease or died at last follow-up. None of the recipients had malignant transformation of AML. CONCLUSION: These findings are reassuring for the safety of donors with AML (without TSC or LAM) as well as their recipients without evidence of malignant transformation of AML. As such, this can also positively impact the donor pool by increasing the number of available kidneys. Wolters Kluwer - Medknow 2021 2021-01-19 /pmc/articles/PMC8052899/ /pubmed/33897168 http://dx.doi.org/10.4103/UA.UA_14_20 Text en Copyright: © 2021 Urology Annals https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Anton, Desiree Garcia
Kovvuru, Karthik
Kanduri, Swetha R
Aeddula, Narothama Reddy
Bathini, Tarun
Thongprayoon, Charat
Kaewput, Wisit
Wijarnpreecha, Karn
Watthanasuntorn, Kanramon
Salim, Sohail Abdul
Matemavi, Praise
Vaitla, Pradeep
Rivera, Franco Cabeza
Cheungpasitporn, Wisit
Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review
title Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review
title_full Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review
title_fullStr Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review
title_full_unstemmed Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review
title_short Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review
title_sort use and outcomes of kidneys from donors with renal angiomyolipoma: a systematic review
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052899/
https://www.ncbi.nlm.nih.gov/pubmed/33897168
http://dx.doi.org/10.4103/UA.UA_14_20
work_keys_str_mv AT antondesireegarcia useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT kovvurukarthik useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT kanduriswethar useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT aeddulanarothamareddy useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT bathinitarun useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT thongprayooncharat useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT kaewputwisit useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT wijarnpreechakarn useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT watthanasuntornkanramon useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT salimsohailabdul useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT matemavipraise useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT vaitlapradeep useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT riverafrancocabeza useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview
AT cheungpasitpornwisit useandoutcomesofkidneysfromdonorswithrenalangiomyolipomaasystematicreview